BD develops self-injection delivery system for biologic therapies

摘要

Advances in large-molecule biologic treatments-and the emerging shift of care from hospitals and clinics to the home-are two of the factors influencing the ever- evolving healthcare market. To address these issues, BD Medical, a segment of Becton, Dickinson and Co. is developing the BD? Microinfusor patch injector. Not yet in use commercially, the BD Microinfusor patch injector offers patients an advanced drug delivery system that allows them to self-administer a biologic therapy as opposed to traveling to and from an acute-care facility such as a hospital, clinic, or doctor's office for an injection. BD says that for patients with dexterity issues, particularly the elderly, the BD Microinfusor patch injector offers an easier delivery method than autoinjectors or pens.